The role of miR-206 in the epidermal growth factor (EGF) induced repression of estrogen receptor-α (ERα) signaling and a luminal phenotype in MCF-7 breast cancer cells

Molecular Endocrinology

Volumn 23, Issue 8, 2009, Pages 1215-1230

  Adams, Brian D ^a   Cowee, Danielle M ^b   White, Bruce A ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b UNIVERSITY OF SAINT JOSEPH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANTAGOMIR 206; BIOLOGICAL MARKER; COMPLEMENTARY RNA; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR ALPHA; LUCIFERASE; MESSENGER RNA; MICRORNA; MIR 206; MITOGEN ACTIVATED PROTEIN KINASE; SMALL INTERFERING RNA; STEROID RECEPTOR COACTIVATOR 1; STEROID RECEPTOR COACTIVATOR 3; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL LEVEL; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG MECHANISM; ESTROGEN RESPONSIVE ELEMENT; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NEGATIVE FEEDBACK; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; EPIDERMAL GROWTH FACTOR; ESTROGEN RECEPTOR ALPHA; HUMANS; IN SITU NICK-END LABELING; MICRORNAS; MODELS, BIOLOGICAL; MODELS, GENETIC; OPEN READING FRAMES; PHENOTYPE; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRYPAN BLUE;

EID: 67749113293     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2009-0062     Document Type: Article

References (66)

1. Culhane AC, Howlin J 2007 Molecular profiling of breast cancer: transcriptomic studies and beyond. Cell Mol Life Sci 64:3185-3200
2. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, Liu Y, Nanda R, Tretiakova M, Ruiz Orrico A, Dreher D, Palazzo JP, Perreard L, Nelson E, Mone M, Hansen H, et al. 2006 The molecular portraits of breast tumors are conserved across microarray platforms.BMCGenomics 7:96-107
3. Mullan PB, Millikan RC 2007 Molecular subtyping of breast cancer: opportunities for new therapeutic approaches. Cell Mol Life Sci 64:3219-3232
4. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM 2006 Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19:264-271
5. Rakha EA, Reis-Filho JS, Ellis IO 2008 Impact of basal-like breast carcinoma determination for a more specific therapy. Pathobiology 75:95-103
6. Korsching E, Jeffrey SS, Meinerz W, Decker T, Boecker W, Buerger H 2008 Basal carcinoma of the breast revisited: an old entity with new interpretations. J Clin Pathol 61:553-560
7. Kobayashi S 2008 Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance. Breast Cancer 15:153-158
8. LaMarca HL, Rosen JM 2008 Minireview: hormones and mammary cell fate - what will I become when I grow up? Endocrinology 149:4317-4321
9. Kakarala M, Wicha MS 2008 Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 26:2813-2820
10. Dontu G, El-Ashry D, Wicha MS 2004 Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab 15:193-197
11. Allred DC, Brown P, Medina D 2004 The origins of estrogen receptor α-positive and estrogen receptor α-negative human breast cancer. Breast Cancer Res 6:240-245
12. Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D 2006 Activation of mitogen-activated protein kinase in estrogen receptor α-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor α-negative human breast tumors. Cancer Res 66:3903-3911
13. Sengupta S, Jordan VC 2008 Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance. Adv Exp Med Biol 630:206-219
14. Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, Rimawi M, Osborne CK 2005 Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol 56(Suppl 1):10-20
15. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El-Ashry D 2001 Hyperactivation of MAPK induces loss of ERα expression in breast cancer cells. Mol Endocrinol 15:1344-1359
16. El-Ashry D, Miller DL, Kharbanda S, Lippman ME, Kern FG 1997 Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis. Oncogene 15:423-435
17. Holloway JN, Murthy S, El-Ashry D 2004 A cytoplasmic substrate of mitogen-activated protein kinase is responsible for estrogen receptor-α downregulation in breast cancer cells: the role of nuclear factor-κB. Mol Endocrinol 18:1396-1410
18. Bartel DP 2004 MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-297
19. Bushati N, Cohen SM 2007 microRNA functions. Annu Rev Cell Dev Biol 23:175-205
20. Flynt AS, Lai EC 2008 Biological principles of microRNA-mediated regulation: shared themes amid diversity. Nat Rev Genet 9:831-842
21. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM 2005 MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65:7065-7070
22. Kondo N, Toyama T, Sugiura H, Fujii Y, Yamashita H 2008 miR-206 Expression is down-regulated in estrogen receptor α-positive human breast cancer. Cancer Res 68:5004-5008
23. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, Ellis IO, Tavaré S, Caldas C, Miska EA 2007 MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 8:R214-R229
24. Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, Fedele V, Ginzinger D, Getts R, Haqq C 2006 Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 5:24-37
25. Sempere LF, Christensen M, Silahtaroglu A, Bak M, Heath CV, Schwartz G, Wells W, Kauppinen S, Cole CN 2007 Altered microRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 67:11612-11620
26. Iorio MV, Casalini P, Tagliabue E, Ménard S, Croce CM 2008 MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. Eur J Cancer 44:2753-2759
27. Calin GA, Croce CM 2006 MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 66:7390-7394
28. Barbarotto E, Schmittgen TD, Calin GA 2008 MicroRNAs and cancer: profile, profile, profile. Int J Cancer 122:969-977
29. Adams BD, Guttilla IK, White BA 2008 Involvement of microRNA in breast cancer. Semin Reprod Med 26:522-536
30. Sassen S, Miska EA, Caldas C 2008 MicroRNA: implications for cancer. Virchows Arch 452:1-10
31. Ma L, Weinberg RA 2008 Micromanagers of malignancy: role of microRNA in regulating metastasis. Trends Genet 24:448-456
32. Zhang B, Pan X, Cobb GP, Anderson TA 2007 microRNA as oncogenes and tumor suppressors. Dev Biol 302:1-12
33. Adams BD, Furneaux H, White BA 2007 The micro-ribonucleic acid (microRNA) miR-206 targets the human estrogen receptor-α(ERα) and represses ERα messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol 21:1132-1147
34. Martinez NJ, Ow MC, Barrasa MI, Hammell M, Sequerra R, Doucette-Stamm L, Roth FP, Ambros VR, Walhout AJ 2008 A C. elegans genome-scale microRNA network contains composite feedback motifs with high flux capacity. Genes Dev 22:2535-2549
35. Wilson BJ, Giguère V 2008 Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor α pathway. Mol Cancer 7:49-56
36. Voduc D, Cheang M, Nielsen T 2008 GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value. Cancer Epidemiol Biomarkers Prev 17:365-373
37. Asselin-Labat ML, Sutherland KD, Barker H, Thomas R, Shackleton M, Forrest NC, Hartley L, Robb L, Grosveld FG, van der Wees J, Lindeman GJ, Visvader JE 2007 Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol 9:201-209
38. Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z 2006 GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 127:1041-1055
39. Xu J, Li Q 2003 Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol Endocrinol 17:1681-1692
40. Smith CL, O'Malley BW 2004 Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25:45-71
41. Lonard DM, O'Malley BW 2007 Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Mol Cell 27:691-700
42. Duong V, Augereau P, Badia E, Jalaguier S, Cavailles V 2008 Regulation of hormone signaling by nuclear receptor interacting proteins. Adv Exp Med Biol 617:121-127
43. Wolf IM, Heitzer MD, Grubisha M, DeFranco DB 2008 Coactivators and nuclear receptor transactivation. J Cell Biochem 104:1580-1586
44. Kouros-Mehr H, Kim JW, Bechis SK, Werb Z 2008 GATA-3 and the regulation of the mammary luminal cell fate. Curr Opin Cell Biol 20:164-170
45. Eeckhoute J, Keeton EK, Lupien M, Krum SA, Carroll JS, Brown M 2007 Positive cross-regulatory loop ties GATA-3 to estrogen receptor α expression in breast cancer. Cancer Res 67:6477-6483
46. Nawaz Z, Lonard DM, Smith CL, Lev-Lehman E, Tsai SY, Tsai MJ, O'Malley BW 1999 The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily. Mol Cell Biol 19:1182-1189
47. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS 2004 Human microRNA targets. Plos Biol 2:363-380
48. Dennis G, Sherman B, Hosack D, Yang J, Gao W, Lane H, Lempicki R 2003 DAVID: database for annotation, visualization, and integrated discovery. Genome Biol 4:R60-R70
49. Peppercorn J, Perou CM, Carey LA 2008 Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest 26:1-10
50. Yan J, Tsai SY, Tsai MJ 2006 SRC-3/AIB1: transcriptional coactivator in oncogenesis. Acta Pharmacol Sin 27:387-394
51. Hossain A, Kuo MT, Saunders GF 2006 Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol Cell Biol 26:8191-8201
52. Viger RS, Guittot SM, Anttonen M, Wilson DB, HeikinheimoM2008 Role of the GATA family of transcription factors in endocrine development, function, and disease. Mol Endocrinol 22:781-798
53. Burgess AW 2008 EGFR family: structure physiology signalling and therapeutic targets. Growth Factors 26:263-274
54. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE 2001 Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells. Cancer Res 61:7025-7029
55. Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, Leedman PJ 2009 Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem 284:5731-5741
56. Weiss GJ, Bemis LT, Nakajima E, Sugita M, Birks DK, Robinson WA, Varella-Garcia M, Bunn Jr PA, Haney J, Helfrich BA, Kato H, Hirsch FR, FranklinWA2008 EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol 19:1053-1059
57. Ogawa Y, Hai E, Matsumoto K, Ikeda K, Tokunaga S, Nagahara H, Sakurai K, Inoue T, Nishiguchi Y 2008 Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol 13:431-435
58. Kishimoto T 2005 Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 23:1-21
59. Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay JY 2003 Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer 88:1721-1726
60. Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B, Bromberg JF 2007 Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117:3846-3856
61. Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, Ceccarelli C, Santini D, Paterini P, Marcu KB, Chieco P, Bonafè M2007 IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 117:3988-4002
62. Cheung J, Mak YT, Papaioannou S, Evans BA, Fogelman I, HampsonG2003 Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor κB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-β oestradiol and raloxifene. J Endocrinol 177: 423-433
63. Ogura E, Kageyama K, Hanada K, Kasckow J, Suda T 2008 Effects of estradiol on regulation of corticotropin-releasing factor gene and interleukin-6 production via estrogen receptor type β in hypothalamic 4B cells. Peptides 29:456-464
64. Hobert O 2006 Architecture of a microRNA-controlled gene regulatory network that diversifies neuronal cell fates. Cold Spring Harb Symp Quant Biol 71:181-188
65. Li X, Carthew RW 2005 A microRNA mediates EGF receptor signaling and promotes photoreceptor differentiation in the Drosophila eye. Cell 123:1267-1277
66. McCarthy JJ 2008 MicroRNA-206: the skeletal muscle-specific myomiR. Biochim Biophys Acta 1779:682-691